Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Shuang, Cui, Zhao, Wang, Xin, Zhang, Yi-miao, Wang, Fang, Cheng, Xu-yang, Meng, Li-qiang, Zhou, Fu-de, Liu, Gang, Zhao, Ming-hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172988/
https://www.ncbi.nlm.nih.gov/pubmed/34095173
http://dx.doi.org/10.3389/fmed.2021.663680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172988/
https://www.ncbi.nlm.nih.gov/pubmed/34095173
http://dx.doi.org/10.3389/fmed.2021.663680

Ejemplares similares